• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

从单一血样估算药物的消除速率常数或半衰期:一种对危重症/脆弱患者有特殊益处的实用方法。

Estimating a drug's elimination rate-constant or half-life from a single blood sample: a practical approach with particular benefits for critically ill/vulnerable patients.

作者信息

Scutt Greg, Allen Marcus, Waxman David

机构信息

School of Pharmacy and Biomolecular Sciences, University of Brighton, Brighton, UK.

Centre for Computational Systems Biology, ISTBI, Fudan University, Shanghai, PR China.

出版信息

Biosystems. 2019 Oct;184:103996. doi: 10.1016/j.biosystems.2019.103996. Epub 2019 Jul 29.

DOI:10.1016/j.biosystems.2019.103996
PMID:31369834
Abstract

In this paper we present a mathematical solution that allows the elimination rate-constant or half life of a drug to be estimated from a single blood drug measurement. This is of great utility in clinical areas involving care of criticallly ill or vulnerable patients, where providing more than one blood sample can involve significant risks. The calculations used in our approach, based solely on a single sample, do not require complex pharmacokinetic software, but instead can be simply performed at the patient's bedside using standard personal computing tools. The proposed method allows a personalised estimate of the drug's half life, which is preferable to using population averages, or using estimates based on proxy markers of lagging organ function, which are both indirect and generally inaccurate for a patient with confounding factors.

摘要

在本文中,我们提出了一种数学解决方案,可根据单次血液药物测量值估算药物的消除速率常数或半衰期。这在涉及重症或脆弱患者护理的临床领域非常有用,因为采集多份血样可能会带来重大风险。我们的方法所使用的计算仅基于单个样本,不需要复杂的药代动力学软件,而是可以使用标准个人计算工具在患者床边简单地进行。所提出的方法能够对药物半衰期进行个性化估算,这比使用总体平均值或基于滞后器官功能替代标志物的估算更可取,后两者都是间接的,并且对于有混杂因素的患者通常不准确。

相似文献

1
Estimating a drug's elimination rate-constant or half-life from a single blood sample: a practical approach with particular benefits for critically ill/vulnerable patients.从单一血样估算药物的消除速率常数或半衰期:一种对危重症/脆弱患者有特殊益处的实用方法。
Biosystems. 2019 Oct;184:103996. doi: 10.1016/j.biosystems.2019.103996. Epub 2019 Jul 29.
2
Dose adjustment strategy for oral microemulsion formulation of cyclosporine: population pharmacokinetics-based analysis in kidney transplant patients.环孢素口服微乳剂的剂量调整策略:肾移植患者基于群体药代动力学的分析
Ther Drug Monit. 2004 Jun;26(3):287-94. doi: 10.1097/00007691-200406000-00012.
3
Elimination half-life of drugs: value and limitations.药物的消除半衰期:价值与局限性。
Annu Rev Med. 1985;36:421-7. doi: 10.1146/annurev.me.36.020185.002225.
4
A critical appraisal of cyclosporine A pharmacokinetics in pediatric kidney transplantation using a microemulsion galenic formulation (Neoral).
Transplant Proc. 1998 Aug;30(5):1666-7. doi: 10.1016/s0041-1345(98)00384-4.
5
Concomitant cyclosporine and micafungin pharmacokinetics in healthy volunteers.健康志愿者中环孢素与米卡芬净的药代动力学
J Clin Pharmacol. 2005 Aug;45(8):954-60. doi: 10.1177/0091270005278601.
6
Abbreviated AUC strategy for monitoring cyclosporine microemulsion therapy in the immediate posttransplant period.
Transplant Proc. 1996 Aug;28(4):2162-3.
7
Pharmacokinetic changes in critical illness.危重病中的药代动力学变化。
Crit Care Clin. 2006 Apr;22(2):255-71, vi. doi: 10.1016/j.ccc.2006.02.011.
8
NONMEM population pharmacokinetic modeling of orally administered cyclosporine from routine drug monitoring data after heart transplantation.基于心脏移植术后常规药物监测数据,对口服环孢素进行NONMEM群体药代动力学建模。
Ther Drug Monit. 1998 Jun;20(3):284-93. doi: 10.1097/00007691-199806000-00008.
9
[Therapeutic monitoring by blood concentrations with the focus on cyclosporin A].[以环孢素A为重点的血药浓度治疗监测]
Ugeskr Laeger. 2001 Apr 2;163(14):2009-12.
10
Study of circadian variation of cyclosporine pharmacokinetics.环孢素药代动力学的昼夜变化研究。
Transplant Proc. 1997 Nov;29(7):2930-1. doi: 10.1016/s0041-1345(97)00733-1.